Holen Sie sich die Stockscreener-App
0.9276
4.37%
-0.0424
Handel nachbörslich:
.92
-0.0076
-0.82%
Geovax Labs Inc Aktie (GOVX) Neueste Nachrichten
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance
GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -
GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Form 8-KCurrent report - ADVFN
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks
Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com
GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting - Yahoo Finance
Geovax Labs is a buy, Roth says - Cantech Letter
GOVX’s 2023 Market Dance: Down -59.51% – Time to Invest? - investchronicle.com
Geovax Labs Inc (GOVX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater - Yahoo Finance
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress - Yahoo Finance
GeoVax to Host Q1 2025 Financial Results Conference Call, Spotlight COVID-19 Vaccine and Cancer Therapy Progress - citybuzz -
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 - The Globe and Mail
GeoVax Bolsters Technical Development with Seasoned Biologics Executive - citybuzz -
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations - The Globe and Mail
Analysts Issue Forecasts for GeoVax Labs FY2029 Earnings - Defense World
HC Wainwright Estimates GeoVax Labs FY2025 Earnings - Defense World
Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50 - Defense World
HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
Q2 EPS Estimates for GeoVax Labs Lowered by Noble Financial - Defense World
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates - Yahoo Finance
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital - Yahoo Finance
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum - Yahoo Finance
Geovax Labs stock hits 52-week low at $0.78 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - marketscreener.com
These Numbers Reveal How Powerful Geovax Labs Inc (NASDAQ: GOVX) Stock Is - stocksregister.com
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Ro - GuruFocus
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Roth Capital | GOVX Stock News - GuruFocus
GeoVax to Present at the Emerging Growth Conference on April 16, 2025 - Yahoo Finance
GeoVax (GOVX) Faces Setback with Termination of COVID-19 Vaccine Project | GOVX Stock News - GuruFocus
GeoVax's COVID-19 Vaccine Study Ended by Funding Agency; Shares Fall - marketscreener.com
GeoVax Labs (GOVX) Faces Setback as BARDA-Funded Trial Ends | GO - GuruFocus
Geovax Labs stock hits 52-week low at $0.78 amid market challenges - Investing.com Canada
GeoVax to Present Clinical Data at Upcoming April Industry Events - Yahoo Finance
GeoVax Labs (GOVX): Price Target Lowered Amid BARDA Project Pause | GOVX Stock News - GuruFocus
GeoVax Labs contract with BARDA terminated By Investing.com - Investing.com South Africa
GeoVax Labs Got Written Notification From Advanced Technology International - MarketScreener
GeoVax tumbles as HHS ends mid-stage COVID vaccine trial - TradingView
GeoVax Labs contract with BARDA terminated - Investing.com
Geovax labs director John Spencer buys $9,800 in stock - Investing.com Australia
GeoVax Labs (NASDAQ:GOVX) Earns “Buy” Rating from D. Boral Capital - Defense World
Geovax labs director John Spencer buys $9,800 in stock By Investing.com - Investing.com Canada
Geovax labs VP John Sharkey acquires $5,940 in common stock By Investing.com - Investing.com Canada
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):